In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

ESC Pushing for EU Research Funding

Horizon Europe: The Next EU Framework Programme for Research (2021-2027)

Horizon Europe, the incoming EU framework programme for research, will soon succeed Horizon 2020. This will have a direct impact on EU funds available for health research in the future. Under Horizon Europe the ESC is calling for CVD-specific calls to tackle the burden of disease and drive excellence in research.



Strategic Research Agenda for Cardiovascular Diseases (SRA-CVD)

The Strategic Research Agenda for Cardiovascular Diseases (SRA-CVD) developed by ERA-CVD, a European Research Area Network (ERA-NET), is a blueprint for shaping CVD research priorities in Horizon Europe.

The ESC has significantly contributed as a member of the Advisory Board of ERA CVD. This Strategic Research Agenda (SRA) proposes 15 topics for CVD research in three categories: prevention strategies; treatment and management; and living with chronic cardiovascular diseases.

Among the topics are:

  • Can wearables help people improve and maintain a healthy lifestyle?
  • How to anticipate and prevent heart attack, cardiac arrest and stroke.
  • Using data on genetics, physical and mental health and socioeconomic status to tailor risk assessment, lifestyle advice and preventive treatment.
  • How CVD interacts with cancer and diabetes and the potential for combined treatments.
  • Clarifying the biological, behavioural and social mechanisms of CVD in women versus men.
  • Understanding the crosstalk between cognitive decline and CVD to jointly tackle both conditions.
  • Ways to support CVD patients with depression, anxiety and extreme tiredness.
  • What CVD patients and caregivers need and expect from healthcare providers at the end of life.
  • Research on new advanced cell-derived therapies to detain the progression of acute heart disease to heart failure.

There is false optimism that cardiovascular disease (CVD) is no longer a major public health problem. In Europe, more than 10,000 patients die of CVD every day. CVD is expected to remain the top reason for death, premature death and disease burden in Europe over the next 20 years.

ERA–CVD is conducting an online survey for patients, the public, healthcare providers and research scientists to rank the 15 topics in order to identify the most pressing research priorities.

Implementation of the proposed research agenda will require action at EU and national level from ministries, funding agencies, healthcare administrators and the private sector.

ESC Press Release